Status:
COMPLETED
Efficacy and Safety of Acitretin Plus Pioglitazone in Patients With Psoriasis
Lead Sponsor:
Post Graduate Institute of Medical Education and Research, Chandigarh
Conditions:
Psoriasis
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
Acitretin, when given in combiantion with pioglitazone might achieve better and/or more rapid control of moderate to severe chronic plaque type psoriasis.
Eligibility Criteria
Inclusion
- Patients with chronic plaque type psoriasis having body surface area involvement of \> 20%
- Patients of either sex
- Females who have completed their family and are tubectomized or are postmenopausal i.e. no menstrual bleeding over at least 1 year
- Age range 18-65 years
Exclusion
- Females of child bearing potential
- H/O hypersensitivity to acitretin
- Impaired hepatic function (serum bilirubin, AST, ALT and alkaline phosphatase \>1.5 times the upper limit of normal)
- Impaired renal function (serum creatinine \>1.5mg% in males and \>1.4 mg% in females)
- Hyperlipidemia
- BMI \>30 kg /m2
- H/O excessive alcohol use
- Diabetes mellitus
- Congestive heart failure
- Ischemic heart disease
Key Trial Info
Start Date :
December 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2008
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT00395941
Start Date
December 1 2006
End Date
December 1 2008
Last Update
March 20 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
PGIMER
Chandigarh, India, 160012